A study to assess real world efficacy of antibody cocktail therapy (combined casirivimab and imdevimab) on risk of hospitalization or death among high-risk patients with COVID-19
Latest Information Update: 12 Apr 2022
At a glance
- Drugs Casirivimab/imdevimab (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
Most Recent Events
- 12 Apr 2022 New trial record
- 01 Apr 2022 Results published in the International Journal of Infectious Diseases